ABAC Therapeutics Announces €16 Million Series A to develop therapeutic solutions to fight antibiotic-resistant bacteria

ABAC Therapeutics Announces €16 Million Series A to develop therapeutic solutions to fight antibiotic-resistant bacteria

BARCELONA, Spain – February 15th, 2018 — ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

Full PR available here